Mylan’s promised half-price EpiPen not available until year’s end

pharmafile | October 5, 2016 | News story | Research and Development, Sales and Marketing Mylan, epipen 

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised it would arrive “in several weeks” in August.

Mylan’s authorised generic version of its flagship epinephrine auto-injector will cost $300 for a twin-pack, half the brand version pricetag which has which has been drawing so much fire recently as the company tries to neutralise its recent price-hike controversy. In a statement on 29 August, Mylan stated that it expected to introduce the discounted version “in several weeks”, but has now backtracked, declining to be any more specific on when it will become available than “by the end of the year”, citing inventory and packaging concerns.

This follows CEO Heather Bresch’s appearance before US lawmakers to defend the company’s much-maligned move, and the revelation this week that she intentionally misrepresented profits made from EpiPen during the hearing.

“We expect to launch this year once we have assured that sufficient inventory will be available to meet anticipated orders, created the necessary packaging for the product, and created the necessary labelling for the product,” commented Mylan spokesperson Nina Devlin. “We are diligently working to complete these efforts in order to provide the generic as soon as possible.”

Pfizer, who manufactures the brand version of EpiPen for Mylan, has not indicated any issues which would delay production of the authorised generic. At the beginning of the week, Mylan’s share price was down 21% on 19 August.

Matt Fellows

Related Content

Pfizer to pay $345 million in EpiPen lawsuit

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …


Mylan reaches agreement with Aspen for their European thrombosis business

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …


Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

Latest content